KLK3 and posterior cortical atrophy: Currently, clinicians primarily rely on clinical parameters, such as prostate-specific antigen (PSA) levels, imaging assessments, and histopathological evaluations (including the Gleason score), to guide treatment decisions for patients with PCa (4, 5).